© 2026 Sinochem Nanjing Corporation,
All Right Reserved
Cefotiam Hydrochloride belongs to the second generation of cephalosporin antibiotics, born from a wave of antibacterial innovation in the late 1970s and early 1980s. European and Japanese researchers pushed for cephalosporins that could fight a broad range of bacteria while surviving the bacterial enzymes that wiped out older antibiotics. Pharmaceutical companies fine-tuned the molecular core—3-cephem structure—through tireless rounds of tweaking, always looking for an edge over resistance and side effects. The hydrochloride salt version of cefotiam appeared as scientists sought greater stability and better shelf life, even under the harsh conditions of hospital storage and transport. Today, hospitals rely on cefotiam hydrochloride as a go-to for everything from complicated respiratory infections to septicemia and surgical prophylaxis.
Glancing down at a vial of cefotiam hydrochloride, you notice the white or slightly yellowish crystalline powder, odorless, with a bitter tinge. The water-soluble nature proves practical, making it easy to reconstitute for both intravenous and intramuscular administration. Looking further at its structure, you’ll find a β-lactam ring and a dihydrothiazine ring—classic markers of cephalosporins. The hydrochloride salt not only boosts solubility but extends stability, deterring the breakdown of the active molecule. The molecular formula, C18H18N7O5S3·HCl, and its molecular weight (526.05 g/mol for the hydrochloride version) map out a workhorse molecule, designed with precision.
Pharmaceutical standards for cefotiam hydrochloride run tight. Genuine cefotiam hydrochloride powder must meet sterility thresholds, showing no contamination or pyrogenic activity. Labeling standards sharpens the focus: vials detail dosage strength, batch number, and storage conditions (“store below 25°C and protect from light”). Regulatory authorities demand a precise assay value, often around 90-110% of label claim for drug content. The fine print on the packaging covers shelf life, details of reconstitution, transportation requirements, and potential contaminants. All this is crucial, especially during hospital audits and quality control processes.
Synthesizing cefotiam hydrochloride is a multistep dance that begins with the β-lactam core, an ingredient derived from 7-aminocephalosporanic acid (7-ACA). Chemical engineers tack on various side chains—one at C-3 and another at C-7—using acylation and alkylation reactions, which shape antibacterial performance and protect the molecule against enzymatic shredding from bacterial β-lactamase. The crude cefotiam is then turned into its hydrochloride salt by dissolving it in an appropriate solvent, followed by treatment with hydrogen chloride gas or aqueous HCl, all under tightly controlled pH conditions to avoid damaging the fragile β-lactam bond. Once crystallized, the pure substance gets filtered, washed, dried, and packed, always under sterile conditions to meet pharmaceutical standards. This process demands close monitoring—one slip, and yields drop or impurities climb.
One of the secrets to cefotiam’s strength lies in its chemical modifications. Early chemists learned that swapping out different side groups could dodge the chemical scissors of β-lactamase enzymes. Introducing an aminothiazolyl group unlocked more resilience against Gram-negative bacteria. In the chemistry lab, researchers experiment with further tweaks, such as adding hydrophilic substituents, aiming for better penetration into tough-to-reach tissues. Under controlled conditions, cefotiam also resists hydrolysis much better than many first-generation drugs. The hydrochloride version handles stress—heat, moisture, exposure to air—better than the free base. These adjustments aren’t just chemical trivia; they’re why cefotiam can crack open infections that brush off other antibiotics.
Walking into a pharmacy or hospital storeroom, you might see cefotiam hydrochloride labeled under brands like Pansporin, Cefotiam Hexal, or Cefatim. Some documents use chemical names like 7β-[2-(2-Aminothiazol-4-yl)-2-(methoxyimino)acetamido]ceph-3-em-4-carboxylate hydrochloride or just refer to its salt as cefotiam HCl. These names show up in everything from prescribing software to customs documents, so recognizing each synonym shields against confusion during procurement and prescription.
No one in a hospital wants to play fast and loose with antibiotics. Strength and sterility matter: impurities or microbial contamination can spark real disasters. Proper handling of cefotiam hydrochloride includes gloves and sterile equipment, with strict separation from unrelated pharmaceuticals, especially those vulnerable to cross-contamination like insulin or vaccine vials. Training sessions in hospitals always highlight storage—cool, dry, and away from direct sunlight—and correct reconstitution just prior to injection. Beyond the pharmacy, staff remain on watch for allergic reactions and signs of superinfection, following the latest guidance from pharmacovigilance authorities and the hospital’s infection committee. There’s no skipping steps when patient safety hangs in the balance.
Nothing brings out the value of a drug like a tough infection. Cefotiam hydrochloride steps up for conditions like complicated urinary tract infections, lower respiratory tract infections, and serious skin and soft tissue infections. Surgeons lean on its fast reconstitution and broad antibacterial coverage during operations, especially for procedures at high risk of post-op infection. Pediatric wards order cefotiam for children with mixed or unknown infections. Elderly patients with comorbidities also benefit from cefotiam’s safety profile, which rarely triggers the kind of renal or hematological side effects that knock out competing drugs. Infectious disease specialists keep it in reserve as part of combination regimens for stubborn, resistant infections. None of these uses come by accident; they’re built on years of trial, observation, and adaptation to local patterns of resistance.
Academic labs and pharmaceutical companies race to stay ahead of bacterial resistance. Researchers set their sights on modifications to the cefotiam core, aiming for even greater β-lactamase stability or improved pharmacokinetics. Recent projects look into nanoparticle delivery systems that might shuttle cefotiam through difficult tissue barriers or release the drug slowly over time. Chemists in industry work on purer, more stable salts, and faster, less resource-intensive synthesis routes, hoping to cut production costs and environmental waste. Clinical trial groups look at head-to-head comparisons between cefotiam and newer cephalosporins or carbapenems, picking out patient subgroups that might benefit from targeted use. Doctors and pharmacists now lean on large-scale surveillance studies to track real-world effectiveness in an era where hospital superbugs return with greater force and unpredictability.
Testing the toxicity of cefotiam hydrochloride remains a cornerstone of responsible drug production and clinical use. Preclinical safety tests in animals check for damage to the liver, kidneys, and hematopoietic system. Clinical trials follow patient blood panels for early signals of harm. Most patients handle cefotiam without trouble, but dosing mistakes or hidden allergies can bring trouble quickly—rash, fever, eosinophilia, or rarely, anaphylactic shock. Specialist researchers track rare side effects, such as nephrotoxicity or the so-called “red man” syndrome, which—while more common with other antibiotics—can sometimes pop up when protocols stray from recommended infusion times. Post-marketing surveillance programs collect data from thousands of patients, looking for signals of toxicities too rare to appear in clinical trials.
Antibiotic resistance won’t be going away soon. Pharmaceutical companies keep looking for novel side chain modifications, smarter formulations, and drug combinations that use cefotiam hydrochloride as a core ingredient. With tighter budgets and the slow grind of antibiotic discovery, interest grows in recycling or repurposing older molecules like cefotiam, especially as worldwide shortages of newer agents hit hard. Biotechnology startups toy with “rescue chemistry” to give existing drugs new life through clever modification, and computational chemists simulate how fresh β-lactamase threats could be overcome through tweaks to the cefotiam backbone. In the coming years, cefotiam hydrochloride’s reputation for stability, reliable antibacterial performance, and manageable toxicity could make it even more valuable, especially for hospitals fighting long odds in the global superbug era.
Hospitals rely on a handful of trusted antibiotics to tackle tough infections. Cefotiam hydrochloride sits among those key options. Doctors and pharmacists turn to it for its power against a broad range of bacteria: think pneumonia, urinary tract infections, skin issues, joint infections, and even some tough cases in the abdomen. Developed in Japan, cefotiam’s been around since the 1980s, yet it hasn’t lost relevance.
Life-saving drugs don’t need to be mysterious. Cefotiam belongs to the cephalosporin family. It takes down bacteria by blocking their ability to build strong cell walls. Without those walls, bacteria lose their structure and break apart. Human cells don’t carry these same walls, so the antibiotic singles out harmful microbes without the widespread risk of harming our own tissues.
Many folks hospitalized with burns, bone infections, or severe wounds end up needing strong antibiotics. Cefotiam stands out for its ability to reach high concentrations in body fluids and tissues. This makes it valuable for deep-seated infections that don’t respond well to other medicines.
Pick the wrong antibiotic and the infection doesn’t budge. Too many unnecessary prescriptions, and we breed “superbugs” – bacteria that laugh in the face of our medicines. Cefotiam isn’t handed out blindly. Microbiologists and infectious disease experts run blood or urine cultures to check which bacteria are lurking, then match the treatment. In my time working alongside hospital staff, getting results from these cultures feels like opening a critical piece of mail – it can steer a patient’s recovery.
Not every infection needs a heavy-duty antibiotic. Simple coughs or mild sniffles rarely involve bacteria at all. Throwing broad-spectrum drugs at minor illnesses chips away at their power for the moments we truly need them.
Doctors typically reach for cefotiam in serious situations, or when other medicines fall short. Patients with weak immune systems, the elderly, and young children count on fast, reliable cures. I’ve watched folks spike fevers after surgery, only to turn the corner once this drug kicks in. Having the right tool makes all the difference.
Of course, all medicines come with trade-offs. Cefotiam can cause side effects like any antibiotic: diarrhea, rash, or allergic reactions. Most patients move past them with little trouble, but that underscores the need for skilled monitoring. Knowing the risks, clinicians weigh the evidence and communicate honestly with patients.
Antibiotic resistance doesn’t just threaten hospitals; it lands every family at risk of losing old, reliable cures. I’ve listened to infectious disease teams stress the need for thoughtful drug stewardship. They don’t throw around prescriptions casually. Instead, they keep detailed records, track resistance patterns, and educate both staff and families about proper use.
Public health agencies like the World Health Organization and the CDC offer clear advice: Use strong antibiotics like cefotiam to treat proven bacterial threats. Avoid using them for every cough. Hospitals create guidelines and update them based on the latest data, aiming to keep medications like cefotiam potent for the next generation.
New strains of bacteria keep turning up in clinics and hospitals. The scientific community works overtime to understand which antibiotics still work. They collect samples, study bacterial genes, and test different treatments in real time. Drugs like cefotiam remain part of the solution – as long as everyone uses them with care and respect.
Doctors prescribe Cefotiam Hydrochloride to fight off bacterial infections not tamed by other antibiotics. Stepping into a course of antibiotics, though, often means setting yourself up for more than just a battle with bacteria. Any drug can show a less friendly side, and what I’ve seen in real-world practice is that the common side effects of cefotiam deserve a blunt talk—no sugarcoating, no jargon. Patients appreciate clear expectations. Folks just want to know what could hit them, not a canned answer about “mild” or “severe” reactions.
Most people I’ve spoken with while on cefotiam grumble about stomach discomfort. Nausea and loose stools hit the top of the complaints list. I remember guiding a busy school teacher through a week of mild cramping and off-schedule bathroom trips after his first few doses. The disruption to daily life isn’t minor—stomach issues can make even a simple day hard to handle. Research backs up what patients say: antibiotics like cefotiam often throw the gut’s natural balance out of rhythm, which explains the digestive unrest.
Itchy rashes show up sometimes. For those who already deal with sensitive skin, this can be a real headache. One patient, a young mother, told me she noticed red, patchy spots around her elbows and neck. Nothing life-threatening, but annoying enough to interrupt sleep. Allergic reactions, including hives, can turn a quick recovery into a longer ordeal. Data reviewed from clinical use also lists mild swelling or redness around the injection site, which usually sets in a few hours after a dose.
As a third-generation cephalosporin, cefotiam shares some allergy risk with penicillins. This warning cannot be brushed aside. I’ve watched a colleague treat a case where a seemingly minor rash on day two snowballed into swelling and trouble breathing within hours. Though rare, this danger demands respect. Anyone with a history of allergy to beta-lactam antibiotics needs special attention before starting cefotiam. This isn’t about paranoia, but about simple safety and preventing a bad day from turning much worse.
Cefotiam sometimes nudges blood counts. A routine blood test might pick up mild drops in white cells, or platelets. Only a small percentage of folks will notice—most remain symptom-free—but in a hospital setting, doctors watch out for fever, bruising, or lasting tiredness. Kidneys clear cefotiam from the body, so people with kidney trouble risk building up too much of the drug. Sometimes their bloodwork reveals this before any real soreness or swelling sets in.
Every drug swings a double-edged sword: fighting infection, but chipping away at comfort in the process. Transparency about these side effects keeps trust strong. Patients handle tough news if they know what’s ahead. The best fix, from my own years of watching folks beat infections: don’t tune out your body. If symptoms surprise you or refuse to fade, get help right away. Doctors have seen just about every side effect play out. Open lines of communication keep small problems from growing.
Taking cefotiam with food can ease an upset stomach. Keeping the team in the loop—especially about any new rash or allergic signs—allows for fast changes to the game plan. Patients with kidney concerns need to ask about dose adjustments and plan for bloodwork if therapy will last a while. Simple strategies, basic awareness, and trusting your own instincts always stack the odds in your favor.
Reliable information builds confidence. The U.S. National Library of Medicine, peer-reviewed journals, and the FDA’s drug safety sheets lay out what to expect. That’s not just a list of warnings; it’s the fuel for stronger decisions and fewer unwanted surprises.
Cefotiam hydrochloride steps into the world as an injectable antibiotic. Hospitals turn to it when patients run into tough bacterial infections, especially those found in the lungs, urinary tract, skin, joints, or after surgeries. This medication belongs to the cephalosporin class, which often comes into play when penicillin and its cousins don’t bring enough firepower or cause allergies.
Administration relies on needles—through a vein or muscle. I’ve seen nurses prepare cefotiam in vials, dissolving the powder with sterile water. They check for full dissolution, no chunks or floating matter, and draw it up into a syringe. Delivering it by IV drip often takes about 30 to 60 minutes, and a direct muscle shot can feel sharp but passes quickly. Oral forms just don’t exist for cefotiam, making hospital and clinic settings the only option for treatment.
Injectable antibiotics like cefotiam give an edge in tough or fast-moving cases. Bodies break down many antibiotics if swallowed, making injections the only road to quick, dependable blood levels. Bacterial infections don’t wait around. Delayed treatment, especially in serious pneumonia or sepsis, can risk organ failure or even life.
Sitting on the other side of the needle, the process feels personal. Many patients walking into emergency rooms expect a round of pills and go home. But for my grandfather, legs swollen and fever spiking after a knee surgery, the staff hooked up a drip. Nurses watched for reactions, flushed IV tubes with saline, and made sure he stayed hydrated and comfortable. His infection needed all the antibiotic could give.
Not every antibiotic fits every patient. Some folks have backgrounds of serious rashes or breathing trouble from antibiotics—especially from penicillins or related drugs. Doctors run through allergy lists and weigh options with care. In the rare case of a reaction, folks need quick access to emergency treatment. Multiple hospital protocols guide the whole staff—from drug preparation to checking all details before injecting.
Doctors don’t turn to cefotiam automatically. Lab tests on bacteria from sputum, urine, or wounds help clinics decide which antibiotic stands a chance. Prescribing something too broad or too often risks fueling resistance. Stewardship teams build policies, tracking which medications work and which bacteria are starting to get wise. They keep data updated, teaching younger doctors about options and pitfalls.
Giving any antibiotic by injection means patients need extra support. Hospitals check kidney and liver tests, encourage fluids, and mention possible side effects like rashes or stomach upset. Keeping patients informed turns fear into cooperation, and good communication stops surprises in the middle of treatment. If the IV route causes problems—like vein irritation—teams quickly size up alternatives or adjust the method.
Cefotiam provides a strong shield against many troublesome infections when given the right way. With hands-on care and wise decision-making, healthcare teams and their patients can beat infections that once spelled disaster. It’s about teamwork, vigilance, and keeping skills sharp for those moments when a fast shot of antibiotic can change everything.
People count on antibiotics to fight off stubborn infections. No one enjoys feeling helpless against pneumonia or a UTI. This trust only stretches as far as safety allows. Cefotiam hydrochloride steps in as a cephalosporin, a group of antibiotics built to outmaneuver bacteria resistant to others. Yet, not every body reacts the same way. Recognizing contraindications before starting treatment saves lives, preserves health, and curbs unnecessary suffering.
If someone has ever broken out in hives or worse after taking penicillins or other cephalosporins, using cefotiam risks a repeat—or, in some cases, a much more dangerous reaction. Anaphylaxis is rare, but it hits hard and fast if ignored. Allergists warn that around 10% of people with proven penicillin allergies might react to cephalosporins. In daily practice, no one should push past this risk for the sake of convenience or false reassurance. Screening for recorded allergies matters in every clinic. Patients who seem uncertain about their history do best with extra questions or a careful review from pharmacy records.
Cefotiam heads out of the body through the kidneys. For people living with chronic kidney disease, or anyone who just had their kidneys take a hit—think elderly relatives with slow creatinine clearance—drug levels shoot up quickly. Instead of helping, cefotiam might cause neurotoxicity or even worsen renal function. As a pharmacist once told me, dosing for kidney issues takes more than swapping numbers on a chart; it calls for ongoing checks and clear communication with the care team. For many, alternative antibiotics may fit better, sidestepping these rough waters entirely.
Overuse or the wrong use of broad-spectrum antibiotics opens the door for Clostridium difficile to run wild. That experience can last months and sap all strength from even the toughest patient. Anyone with a history of antibiotic-associated colitis walks a thin line. If someone’s colon already rebelled on cefotiam or another cephalosporin before, the risk probably outweighs the benefit here. Many doctors I’ve spoken with opt for narrower antibiotics, showing respect for past complications.
Cefotiam’s safety story isn’t complete in the youngest children and pregnant women. Animal studies miss crucial details in human growth and fetal development. Without more research, making cefotiam a default choice doesn’t make sense for newborns or during pregnancy, unless options shrink and the infection leaves no wiggle room. Mothers deserve honest discussions about risks to their unborn babies. Many pediatricians reach for older, better-understood alternatives if time is not an enemy.
Healthcare’s not about shortcuts—it’s about making careful, informed choices that put patient well-being first. If questions rise about cefotiam hydrochloride, pharmacists and infectious disease teams give excellent guidance. Checking a person’s history, understanding their body’s limits, and weighing every risk doesn’t slow things down; it keeps everyone safer. Better to pause and check than to rush and regret.
Choosing any medication during pregnancy or breastfeeding sparks worry for many parents and families. Cefotiam Hydrochloride, a cephalosporin antibiotic, comes up in certain infections that need a stronger hand. Folks will want to know if they should take it, especially with the stakes as high as the health of a baby. Doing research helps, but medical jargon can muddy the decision. Over the years of reading clinical updates and conversations with people facing these choices, it’s clear there’s no simple yes or no answer. Getting the facts straight, based on trusted sources, matters more than repeating secondhand advice.
Most drug safety studies avoid testing on pregnant or breastfeeding women for ethical reasons. This gap leaves doctors looking to animal data and scattered case reports. In lab animals, Cefotiam Hydrochloride hasn't shown obvious birth defects at usual doses. That sounds like a green light, but humans don’t always react like lab rats. There’s no record of massive problems linked to this antibiotic in pregnancy, but no long-term trial has ruled out subtle issues, either.
Cephalosporins are not the first line for minor colds, yet when a tough infection won’t quit, options grow thin. Here, the experience of physicians matters. Many have prescribed related antibiotics safely when infection threatened the mother's health more than the drug possibly could. Health Canada and the FDA classify it as generally safe if a health professional judges it absolutely necessary. No system guarantees 100% certainty.
Mothers who breastfeed face another set of worries. Some medicines slip into breast milk, and Cefotiam Hydrochloride does show up there, but usually in very small amounts. Most guidelines say the risk to the baby looks low, especially when treatment lasts only a short time. Still, some infants react with loose stools or a mild rash, since their bodies break down drugs differently than adults. Watching out for any change—poor feeding, new fussiness—gives an early warning if something isn’t right.
Doctors and patients both grumble at the lack of concrete answers. I’ve seen parents spend hours on forums and still walk out of the pharmacy feeling unsure. The best decisions come from honest conversations: What infection are we fighting? Could another antibiotic work with fewer unknowns? Are we treating a mild cough, or are we trying to prevent more dangerous problems? Each person’s medical history colors the answer.
Evidenced-based medicine uses every bit of available data, clinical experience, and the unique story of each patient. The American Academy of Pediatrics and similar groups point out that, if a cephalosporin antibiotic is the only way to beat a tough infection, the benefits far outweigh any small uncertainty. Nobody can erase the worry, but real facts, careful monitoring, and a provider who listens can go a long way. Families deserve plain language explanations—no sugarcoating, but no panic, either.
Pregnancy and breastfeeding do not mean refusing all antibiotics, especially during serious infections. Staying informed, asking pointed questions, and reporting any side effects early will always matter more than relying on blanket statements from the internet. Medicine keeps changing, but the need for good communication never goes out of style.
| Names | |
| Preferred IUPAC name | (6R,7R)-7-[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetamido]-3-[(5-methyl-1,3,4-thiadiazol-2-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid hydrochloride |
| Other names |
Tiazin Cefotiamum Hydrochloridum Cefotiam HCl Winatiam |
| Pronunciation | /ˌsɛf.oʊˈtaɪ.əm haɪˈdrɒk.lə.raɪd/ |
| Identifiers | |
| CAS Number | 61438-64-0 |
| Beilstein Reference | 60726 |
| ChEBI | CHEBI:60913 |
| ChEMBL | CHEMBL2105891 |
| ChemSpider | 67444449 |
| DrugBank | DB01331 |
| ECHA InfoCard | InfoCard 100.217.115 |
| EC Number | 62147-49-3 |
| Gmelin Reference | 1073836 |
| KEGG | D00251 |
| MeSH | D002494 |
| PubChem CID | 65634 |
| RTECS number | UY2975000 |
| UNII | 0KHY51T1I2 |
| UN number | UN2811 |
| Properties | |
| Chemical formula | C17H18N8O5S3•HCl |
| Molar mass | 516.99 g/mol |
| Appearance | White or almost white crystalline powder |
| Odor | Odorless |
| Density | 1.9 g/cm³ |
| Solubility in water | Freely soluble in water |
| log P | -2.03 |
| Acidity (pKa) | 2.4 |
| Basicity (pKb) | 6.45 |
| Magnetic susceptibility (χ) | -26.5 × 10⁻⁶ cm³/mol |
| Refractive index (nD) | 1.680 |
| Dipole moment | 7.15 D |
| Pharmacology | |
| ATC code | J01DD16 |
| Hazards | |
| Main hazards | Harmful if swallowed, causes serious eye irritation, may cause respiratory irritation. |
| GHS labelling | GHS07 |
| Pictograms | GHS05, GHS07 |
| Signal word | Warning |
| Hazard statements | Hazard statements: Harmful if swallowed. Causes serious eye irritation. |
| Precautionary statements | Keep container tightly closed. Store in a dry place. Store at room temperature. Avoid breathing dust. Wash thoroughly after handling. |
| NFPA 704 (fire diamond) | NFPA 704: 1-1-0 |
| Flash point | Flash point: 253.4 °C |
| Lethal dose or concentration | LD50 (mouse, IV): 6,300 mg/kg |
| LD50 (median dose) | LD50 (median dose): Mouse intravenous LD50 is 3200 mg/kg |
| NIOSH | Not Listed |
| PEL (Permissible) | PEL: Not established |
| REL (Recommended) | 1-2 g daily in 2 divided doses |
| Related compounds | |
| Related compounds |
Cephapirin Cephalexin Cefotaxime Cefodizime Cefazolin Cefuroxime Cefaclor Cefepime |
